Ironwood (IRWD) Q4 Earnings Miss, Revenues Beat Marginally
https://www.zacks.com/stock/news/2227354/ironwood-irwd-q4-earnings-miss-revenues-beat-marginally?cid=CS-ZC-FT-analyst_blog|earnings_article-2227354
Feb 16, 2024 - Ironwood's (IRWD) fourth-quarter 2023 earnings lag estimates while revenues beat the same marginally. Linzess collaboration revenues drive the top line.
0
Exact Sciences (EXAS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
https://www.zacks.com/stock/news/2226264/exact-sciences-exas-may-report-negative-earnings-know-the-trend-ahead-of-next-week-s-release?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2226264
Feb 14, 2024 - Exact Sciences (EXAS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
0
Quest Diagnostics (DGX) Advances in Cancer Research With New Deal
https://www.zacks.com/stock/news/2216443/quest-diagnostics-dgx-advances-in-cancer-research-with-new-deal?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2216443
Jan 26, 2024 - Quest Diagnostics' (DGX) subsidiary Haystack Oncology collaborates with TriSalus Life Sciences to improve therapeutic options for aggressive forms of cancer.
0
5 Impressive MedTech Industry Growth Stocks to Buy for 2024
https://www.zacks.com/stock/news/2203633/5-impressive-medtech-industry-growth-stocks-to-buy-for-2024?cid=CS-ZC-FT-analyst_blog|investment_ideas-2203633
Dec 29, 2023 - Stocks such as HAE, PEN, EXAS, PODD and CAH are set to garner remarkable growth for investors.
0
Here's Why You Should Retain Exact Sciences (EXAS) Stock Now
https://www.zacks.com/stock/news/2197564/here-s-why-you-should-retain-exact-sciences-exas-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2197564
Dec 13, 2023 - Investors are optimistic about Exact Sciences (EXAS) on strong Cologuard adoption and raised guidance.
0
Pages: 12
<Page 2